How do I install the Es Hcm Ugps6 Mg Phos Monitor skill?

Run npx skillmds@latest add dromlakhani/es-hcm-ugps6-mg-phos-monitor in your terminal (requires Node.js), paste this page's agent-chat prompt into Claude, Cursor, or any MCP-connected agent, or download the SKILL.md file and copy it into your agent's skills directory.

Is Es Hcm Ugps6 Mg Phos Monitor safe to use?

This skill has not completed SkillMD's automated safety review yet. Independent scanners report: SkillSpector: PASS, Skill Scanner: PASS. Capability flags: makes network calls. SkillMD never runs a skill's scripts for you; review the SKILL.md before installing.

Which AI agents work with Es Hcm Ugps6 Mg Phos Monitor?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Is Es Hcm Ugps6 Mg Phos Monitor free to use?

Yes. Installing skills from SkillMD is free, and the skill stays under its author's original license.

Who published Es Hcm Ugps6 Mg Phos Monitor?

dromlakhani (@dromlakhani) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Es Hcm Ugps6 Mg Phos Monitor by dromlakhani

Name: Es Hcm Ugps6 Mg Phos Monitor
Rating: 4.666666666666667 (3 reviews)
Author: dromlakhani

Es Hcm Ugps6 Mg Phos Monitor

The guideline suggests checking serum magnesium and phosphate levels and repleting if low in patients receiving antiresorptive therapy for hypercalcemia of malignancy. Clinicians should consider this when they note electrolyte abnormalities or inquire about supportive care during bisphosphonate or denosumab treatment.

dromlakhani Updated Sep 8, 2026 10 repo stars

File contents

Monitor and replete serum magnesium and phosphate if low during HCM treatment

STEP 1 — Gather Information

Obtain serum magnesium and phosphate levels in adults with hypercalcemia of malignancy who are receiving or about to receive antiresorptive therapy (IV bisphosphonate or denosumab). Document baseline renal function and current medications that may affect electrolytes.

STEP 2 — Rule In / Rule Out

Compare results to laboratory reference ranges: low if magnesium <1.7 mg/dL or phosphate <2.5 mg/dL; normal if at or above these thresholds. Proceed to stratification if either is low.

STEP 3 — Classify or Stratify

If low, classify deficiency severity: mild (Mg 1.4-1.6 mg/dL or PO4 2.0-2.4 mg/dL), moderate (Mg 1.0-1.3 mg/dL or PO4 1.5-1.9 mg/dL), severe (<1.0 mg/dL Mg or <1.5 mg/dL PO4). If normal, continue routine monitoring.

STEP 4 — Decide

For mild deficiency, initiate oral replacement (e.g., magnesium oxide 400 mg daily, phosphate supplement 250-500 mg daily) and recheck in 24-48 hours; for moderate/severe, consider IV replacement under cardiac monitoring and recheck every 12-24 hours until normal; if normal, maintain antiresorptive therapy and repeat electrolytes per institutional protocol.

Clinical Guardrails / Mimics / Pitfalls

Avoid rapid IV magnesium or phosphate infusion in patients with renal insufficiency to prevent hypermagnesemia, hyperphosphatemia, or ectopic calcification; do not replace if serum calcium is rising concurrently without reassessing HCM control; monitor for diarrhea with oral magnesium salts.

Concrete Clinical Example

A 62-year-old woman with lung cancer–related HCM on zoledronic acid reports fatigue; labs show Mg 1.4 mg/dL (low) and PO4 2.0 mg/dL (low). She receives oral magnesium glycinate 500 mg BID and sodium phosphate 500 mg TID; levels normalize after 48 hours; antiresorptive therapy continues without interruption.

Source: Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2023, https://doi.org/10.1210/clinem/dgac621

---name: es-hcm-ugps6-mg-phos-monitordescription: The guideline suggests checking serum magnesium and phosphate levels and repleting if low in patients receiving antiresorptive therapy for hypercalcemia of malignancy. Clinicians should consider this when they note electrolyte abnormalities or inquire about supportive care during bisphosphonate or denosumab treatment.---# Monitor and replete serum magnesium and phosphate if low during HCM treatment## STEP 1 — Gather InformationObtain serum magnesium and phosphate levels in adults with hypercalcemia of malignancy who are receiving or about to receive antiresorptive therapy (IV bisphosphonate or denosumab). Document baseline renal function and current medications that may affect electrolytes.## STEP 2 — Rule In / Rule OutCompare results to laboratory reference ranges: low if magnesium <1.7 mg/dL or phosphate <2.5 mg/dL; normal if at or above these thresholds. Proceed to stratification if either is low.## STEP 3 — Classify or StratifyIf low, classify deficiency severity: mild (Mg 1.4-1.6 mg/dL or PO4 2.0-2.4 mg/dL), moderate (Mg 1.0-1.3 mg/dL or PO4 1.5-1.9 mg/dL), severe (<1.0 mg/dL Mg or <1.5 mg/dL PO4). If normal, continue routine monitoring.## STEP 4 — DecideFor mild deficiency, initiate oral replacement (e.g., magnesium oxide 400 mg daily, phosphate supplement 250-500 mg daily) and recheck in 24-48 hours; for moderate/severe, consider IV replacement under cardiac monitoring and recheck every 12-24 hours until normal; if normal, maintain antiresorptive therapy and repeat electrolytes per institutional protocol.## Clinical Guardrails / Mimics / PitfallsAvoid rapid IV magnesium or phosphate infusion in patients with renal insufficiency to prevent hypermagnesemia, hyperphosphatemia, or ectopic calcification; do not replace if serum calcium is rising concurrently without reassessing HCM control; monitor for diarrhea with oral magnesium salts.## Concrete Clinical ExampleA 62-year-old woman with lung cancer–related HCM on zoledronic acid reports fatigue; labs show Mg 1.4 mg/dL (low) and PO4 2.0 mg/dL (low). She receives oral magnesium glycinate 500 mg BID and sodium phosphate 500 mg TID; levels normalize after 48 hours; antiresorptive therapy continues without interruption.**Source:** Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2023, https://doi.org/10.1210/clinem/dgac621

Frequently asked questions